Michael Wang, MD, is Professor of Lymphoma and Myeloma at MD Anderson Cancer Center where he established the Mantle Cell Lymphoma Program of Excellence, the world’s only program dedicated exclusively to MCL research and treatment. He led trials resulting in 3 FDA approvals for MCL treatment. He leads a large lab focusing on overcoming resistance to MCL therapies and developing new ones. His detailed studies of tissue from patients with MCL has been instrumental in setting the stage for this application. Jia Zhou, PhD, is Professor of Pharmacology and Toxicology at the University of Texas Medical Branch. Apart from academia, he worked in the pharmaceutical industry for 7 years. His primary research interest is drug discovery and the development of novel small-molecule therapeutics for cancers and other diseases. He has established a fruitful collaboration with Dr. Wang and his lab and has great experience in leading both the chemical and pharmacological aspects of drug development.